Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly ...Middle East

Favorable safety profile and effective biochemical control in 52-week trial Significant improvement of acromegaly symptoms vs. standard of care at baseline Improved patient reported treatment satisfaction, convenience, and quality of life LUND, Sweden, July 17, 2023 /PRNewswire/ --...

Hence then, the article about camurus announces new phase 3 data reinforcing long term safety and efficacy of octreotide sc depot cam2029 in patients with acromegaly was published today ( Monday 17/07/2023 - 08:44 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly )

Also on site :

• North Korea says its latest weapons tests included missiles with cluster-bomb warheads
• 1987 No. 1 Hit Ranked Among 'Best Hair Metal Songs of All Time' Became a Powerful Anthem for Starting Over
• Man rescued after two weeks trapped in collapsed Mexico mine